What Levels of Uric Acid and NT-Probnp Predict Outcomes of Eisenmenger Syndrome in Children?

Objective: Noninvasive methods for follow-up of pulmonary hypertensive children are limited. The main aim of this study was to determine the cutoff levels for uric acid and N-terminal pro-brain natriuretic peptide (NT-proBNP) for follow-up of Eisenmenger patients and their relationships with classical methods. To our best knowledge, this is the first study to investigate the levels of NT-proBNP and uric acid in pediatric Eisenmenger patients.Materials and Methods: Sixteen patients with Eisenmenger syndrome and 37 healthy children as controls were included in the study. The serum NT-proBNP and uric acid levels of the participants were measured. The echocardiography, six-minute walk test, and right cardiac catheterization data of the two groups were compared.Results: NT-proBNP>81.4 pg/mL and uric acid >3.5 mg/dL were found to be the most specific and sensitive points for predicting the severity of pulmonary hypertension in Eisenmenger syndrome. There was no significant difference between mean pulmonary arterial pressure and serum NT-proBNP level; however, the differences between pulmonary vascular resistance and serum NT-proBNP level and between mean pulmonary arterial pressure and serum NT-proBNP level were significant. There was no significant difference between NT-proBNP level and New York Heart Association functional classification or six-minute walk test distance. There was no significant difference between serum uric acid level and pulmonary vascular resistance, right atrial pressure, or mean pulmonary arterial pressure.Conclusion: It is too early to determine if serum biomarkers can replace classical diagnostic methods in Eisenmenger syndrome; further studies are required.

Kaynakça

Kurzyna M, Araszkiewicz A, Blaszczak P, Grabka M, Hawranek M, Kopec G, et al. Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint state- ment of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions. Kardiol Pol 2015; 73(1): 63-8. [CrossRef]

Jardim C, Souza R. Biomarkers and prognostic indicators in pulmo- nary arterial hypertension. Curr Hypertens Rep 2015; 17(6): 556. [CrossRef]

Heresi GA. Clinical perspective: biomarkers in pulmonary arterial hy- pertension. Int J Clin Pract Suppl 2011; 169: 5-7. [CrossRef]

Siekmeier R, Grammer T, März W. Role of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J Cardiovasc Pharmacol Ther 2008; 13(4): 279-97. [CrossRef]

Sanli C, Oguz D, Olgunturk R, Tunaoglu FS, Kula S, Pasaoglu H. Elevated homocysteine and asymmetric dimethyl arginine levels in pul- monary hypertension associated with congenital heart disease. Pediatr Cardiol 2012; 33(8): 1323-31. [CrossRef]

Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012; 7(3): 259-67. [CrossRef]

Palmieri V, Manganelli F, Russo C, Gagliardi B, Pezzullo S, Gagliar- di G et al. Accuracy and feasibility of simplified Doppler-based left ventricular ejection fraction. Am J Cardiol 2013; 112(6): 889-94. [CrossRef]

Maron BA. Hemodynamics should be the primary approach to di- agnosing, following, and managing pulmonary arterial hypertension. Can J Cardiol 2015; 31(4): 515-20. [CrossRef]

Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systemat- ic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119(1): 256-70. [CrossRef]

Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60(13): 1192-201. [CrossRef]

Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63(3): 321-7. [CrossRef]

Howard LS. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. Eur Respir Rev 2011; 20(122): 236-42. [CrossRef]

Sargento L, Longo S, Lousada N, Dos Reis RP. Nt-ProBNP, Anaemia and Renal function are independent predictors of hospitalization in outpatients with pulmonary artery hypertension. Rev Port Pneumol (2006) 2015; 21(1): 46-7. [CrossRef]

Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Mait- land M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008; 117(19): 2475-83. [CrossRef]

Das BB, Raj S, Solinger R. Natriuretic peptides in cardiovascular dis- eases of fetus, infants and children. Cardiovasc Hematol Agents Med Chem 2009; 7(1): 43-51. [CrossRef]

Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009; 3: 269-87.

Niedeggen A, Skobel E, Haager P, Lepper W, Mühler E, Franke A. Comparision of the 6-minute walk test with established parameters for assesment of cardiopulmonary capacity in adults with complex congenital cardiac disease. Cardiol Young 2005; 15(4): 385-90. [CrossRef]

Reardon LC, Williams RJ, Houser LS, Miner PD, Child JS, Aboulhosn JA. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome. Am J Cardiol 2012; 110(10): 1523-6. [CrossRef]

Toyono M, Harada K, Tamura M, Aoki-Okazaki M, Shimada S, Oya- mada J, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. Pedi- atr Cardiol 2008; 29(1): 65-9. [CrossRef]

Dhaun N, Vachiery JL, Benza RL, Naeije R, Hwang LJ, Liu X, et al. Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. J Heart Lung Transplant 2014; 33(5): 521-7. [CrossRef]

Baldus S, Köster R, Chumley P, Heitzer T, Rudolph V, Ostad MA, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 2005; 39(9): 1184-90. [CrossRef]

Hayabuchi Y, Matsuoka S, Akita H, Kuroda Y. Hyperuricaemia in cyanotic congenital heart disease. Eur J Pediatr 1993; 152(11): 873- 6. [CrossRef]

Kanbay A, Inonu H, Solak Y, Erden A, Uslu E, Yuksel SA, et al. Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med 2014; 25(5): 471-6. [CrossRef]

Zharikov SI, Swenson ER, Lanaspa M, Block ER, Patel JM, Johnson RJ. Could uric acid be a modifiable risk factor in subjects with pulmo- nary hypertension? Med Hypotheses 2010; 74(6): 1069-74. [CrossRef]

Oya H, Nagaya N, Satoh T, Sakamaki F, Kyotani S, Fujita M, et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000; 84(1): 53-8.[CrossRef]

Kaynak Göster